CKM

AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update

Retrieved on: 
Wednesday, November 15, 2023
Webcast, AIM, Pancreatic cancer, NYSE, Rintatolimod, Investment, Patient, Research, CKM, Event, Conference, Ovarian cancer, Doctor of Philosophy, TNBC, Pharmaceutical industry, Cryptocurrency

OCALA, Fla., Nov. 15, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported financial results for the third quarter 2023 and provided a business update. As previously announced, the Company will host a conference call and webcast today, Wednesday, November 15, 2023, at 8:30 AM ET (details below).

Key Points: 
  • – Will host conference call and webcast today, November 15th at 8:30 AM ET
    OCALA, Fla., Nov. 15, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported financial results for the third quarter 2023 and provided a business update.
  • As previously announced, the Company will host a conference call and webcast today, Wednesday, November 15, 2023, at 8:30 AM ET (details below).
  • We are dedicated to driving our clinical programs forward and building momentum to generate value for our shareholders,” commented Thomas K. Equels, Chief Executive Officer of AIM.
  • As of September 30, 2023, AIM reported cash, cash equivalents and marketable investments of $22.4 million.

AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer

Retrieved on: 
Tuesday, November 14, 2023
CTL, AIM, Safety, NYSE, Senior, Breast cancer, Celecoxib, Roswell Park, Rintatolimod, Paper, Patient, TLR3, Journal, Immunology, CKM, Pembrolizumab, AIM ImmunoTech, Science of team science, Immunotherapy, Doctor of Philosophy, Manuscript, Pharmaceutical industry, Management, Cancer, MD

OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM ImmunoTech Inc.’s drug candidate Ampligen® (also known as rintatolimod), interferon α-2b and celecoxib, followed by pembrolizumab.

Key Points: 
  • OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM ImmunoTech Inc.’s drug candidate Ampligen® (also known as rintatolimod), interferon α-2b and celecoxib, followed by pembrolizumab.
  • The data were published in a manuscript titled, “ Systemic Infusion of TLR3-Ligand and IFNα in Breast Cancer Patients Reprograms Local Tumor Microenvironment for Selective CTL Influx ,” in The Journal for ImmunoTherapy of Cancer.
  • The pilot study evaluated the safety of systemic CKM composed of intravenous rintatolimod (Ampligen; selective TLR3 ligand), interferon α-2b and celecoxib, and the combination’s ability to promote local CTL influx to mTNBC lesions.
  • For more information about the study, please visit ClinicalTrials.gov: NCT03599453 .

Cardiometabolic Health Congress Becomes First Organization to Offer Certification in Cardiometabolic Health

Retrieved on: 
Thursday, November 9, 2023
Knowledge, CCHP, Research, Practitioner, National Center for Health Statistics, CKM, University of Colorado School of Medicine, National Center for Research Resources, Health, Obesity, Physician, Congress, American Heart Association, MD, Certification, Diabetes, Type 2 diabetes, University of Colorado Hospital, Medicine, Hypertension, Annual, Systemic, Kidney disease, University, CMHC, AHA, Pharmacist, Nursing, Dyslipidemia, Atherosclerosis, Pharmaceutical industry

Boca Raton, FL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cardiometabolic Health Congress (CMHC) announced today that learners who complete its Foundations of Cardiometabolic Health Certificate Course now have the opportunity to sit for the Certified Cardiometabolic Health Professional (CCHP) examination.

Key Points: 
  • Boca Raton, FL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cardiometabolic Health Congress (CMHC) announced today that learners who complete its Foundations of Cardiometabolic Health Certificate Course now have the opportunity to sit for the Certified Cardiometabolic Health Professional (CCHP) examination.
  • Regarding the certification announcement, Dr. Eckel said, "I cannot overstate the tremendous implications of having a dedicated certification on the entire field of cardiometabolic health.
  • The Foundations of Cardiometabolic Health Certificate Course is currently open for enrollment to physicians, nurses, residents, fellows, and any other health professional interested in furthering their knowledge in the core principles of cardiometabolic health.
  • Cardiometabolic Health Congress (CMHC) is a single point of access for breakthrough research, comprehensive education, and practical clinical strategies surrounding cardiometabolic health.

Jana Care, Inc. Announces Initial Closing of a $6 Million Financing Round to Complete Commercialization of its Self-administered Blood Tests for Kidney and Heart Disease

Retrieved on: 
Wednesday, November 8, 2023
SingHealth, Conditional sentence, Patient, Harvard Medical School, CKM, Health, American Heart Association, Massachusetts General Hospital, Chronic kidney disease, Quality of life, IAG, Disease, Risk, Creatinine, Potassium, Hospital, Heart failure, ARCH Venture Partners, Pharmaceutical industry, Medicine

The Company's self-administered, quantitative blood testing platform enables remote risk stratification of chronic kidney disease and heart failure patients.

Key Points: 
  • The Company's self-administered, quantitative blood testing platform enables remote risk stratification of chronic kidney disease and heart failure patients.
  • In addition to its ongoing partnerships with global leaders in diagnostic technologies and pharmaceutical development, Jana Care welcomes lead investor IAG Capital Partners.
  • Jana Care will use the funds to expand the development of Jana Care's quantitative blood testing platform.
  • The platform is designed to enable self-administered blood tests at-home and allows clinicians to review the test results remotely as needed.

SIBIONICS Achieves Milestone: Receiving CE Mark for Its Groundbreaking GS1 Continuous Glucose Monitoring System

Retrieved on: 
Wednesday, November 1, 2023
Surbana Jurong, CKM, Health, Family, CE marking, Medtech, Workforce, Certification, Diabetes, MARD, App Store (iOS/iPadOS), Research, Friends, GS1, CGM, Artificial intelligence, Hospital, AGP, Safety, Patient, Medical device, Pharmaceutical industry, EU

SHENZHEN, China, Nov. 1, 2023 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, is delighted to announce that it has received the CE Mark for its revolutionary GS1 CGM.

Key Points: 
  • SHENZHEN, China, Nov. 1, 2023 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, is delighted to announce that it has received the CE Mark for its revolutionary GS1 CGM.
  • Founded in 2015, SIBIONICS boasts a workforce exceeding 700 individuals, with over 40% actively engaged in research and development efforts.
  • The SIBIONICS GS1 CGM offers users 14 days of calibration-free continuous glucose monitoring solution, empowering them with the capability to transmit glucose data to their monitoring devices or mobile applications and generate professional AGP reports.
  • Starting today, SIBIONICS GS1 CGM products will gradually become available for pre-sales in EU countries, the UK, and other European countries.

SIBIONICS Achieves Milestone: Receiving CE Mark for Its Groundbreaking GS1 Continuous Glucose Monitoring System

Retrieved on: 
Wednesday, November 1, 2023
Surbana Jurong, CKM, Health, Family, CE marking, Medtech, Workforce, Certification, Diabetes, MARD, App Store (iOS/iPadOS), Research, Friends, GS1, CGM, Artificial intelligence, Hospital, AGP, Safety, Patient, Medical device, Pharmaceutical industry, EU

SHENZHEN, China, Nov. 1, 2023 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, is delighted to announce that it has received the CE Mark for its revolutionary GS1 CGM.

Key Points: 
  • SHENZHEN, China, Nov. 1, 2023 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, is delighted to announce that it has received the CE Mark for its revolutionary GS1 CGM.
  • Founded in 2015, SIBIONICS boasts a workforce exceeding 700 individuals, with over 40% actively engaged in research and development efforts.
  • The SIBIONICS GS1 CGM offers users 14 days of calibration-free continuous glucose monitoring solution, empowering them with the capability to transmit glucose data to their monitoring devices or mobile applications and generate professional AGP reports.
  • Starting today, SIBIONICS GS1 CGM products will gradually become available for pre-sales in EU countries, the UK, and other European countries.

SIBIONICS to Make Debut at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Retrieved on: 
Sunday, October 1, 2023
CGM, CKM, CE, CLM, Intelligence, Certification, EASD, Carmine Di Sibio, Patient, Algorithm, European, KS1, Artificial intelligence, European Association for the Study of Diabetes, Medical device, Diabetes

SHENZHEN, China, Sept. 30, 2023 /PRNewswire/ -- The 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) is set to take place from October 2nd to 6th, 2023, in Hamburg, Germany.

Key Points: 
  • SHENZHEN, China, Sept. 30, 2023 /PRNewswire/ -- The 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) is set to take place from October 2nd to 6th, 2023, in Hamburg, Germany.
  • Established in 2015, SIBIONICS is a high-tech firm specializing in the integration of implantable medical hardware technology and artificial intelligence algorithms.
  • The product is on the verge of obtaining CE certification from the European Union, promising a more scientifical and personalized approach to diabetes management for global users.
  • Additionally, SIBIONICS will present the SiBio KS1 Continuous Ketone Monitoring (CKM) System, a bio-wearable for metabolic management.

SIBIONICS to Make Debut at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Retrieved on: 
Sunday, October 1, 2023
CGM, CKM, CE, CLM, Intelligence, Certification, EASD, Carmine Di Sibio, Patient, Algorithm, European, KS1, Artificial intelligence, European Association for the Study of Diabetes, Medical device, Diabetes

SHENZHEN, China, Oct. 1, 2023 /PRNewswire/ -- The 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) is set to take place from October 2nd to 6th, 2023, in Hamburg, Germany.

Key Points: 
  • SHENZHEN, China, Oct. 1, 2023 /PRNewswire/ -- The 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) is set to take place from October 2nd to 6th, 2023, in Hamburg, Germany.
  • Established in 2015, SIBIONICS is a high-tech firm specializing in the integration of implantable medical hardware technology and artificial intelligence algorithms.
  • The product is on the verge of obtaining CE certification from the European Union, promising a more scientifical and personalized approach to diabetes management for global users.
  • Additionally, SIBIONICS will present the SiBio KS1 Continuous Ketone Monitoring (CKM) System, a bio-wearable for metabolic management.

AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Bre

Retrieved on: 
Monday, September 11, 2023
CKM, TNBC, Roswell Park Comprehensive Cancer Center, Science of team science, AIM, IV, Senior, DL, Safety, DLT, SITC, Paclitaxel, Immunotherapy, Celecoxib, Cyclophosphamide, Trae tha Truth, Roswell Park, Research, AC, Neoplasm, Biomarker, Doctor of Philosophy, PCR, Assistant, NAC, Patient, Blood, Rintatolimod, Society for Immunotherapy of Cancer, Financial toxicity, Immunology, Infrared spectroscopy correlation table, Physician, NYSE, Medical imaging, Pharmaceutical industry, MD

OCALA, Fla., Sept. 11, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Roswell Park Comprehensive Cancer Center has reported the complete topline data from its Phase 1 study evaluating Ampligen® (rintatolimod) as a component of a CKM regimen for the treatment of early-stage triple negative breast cancer (TNBC). The complete topline results are now available on ClinicalTrials.gov: NCT04081389.

Key Points: 
  • The complete topline results are now available on ClinicalTrials.gov: NCT04081389 .
  • “We are pleased to bolster our growing body of data from Ampligen and the results demonstrated in the Phase 1 study with the completed topline data report now in hand.
  • Secondary endpoints included pCR rate where 5/9 (56%) of patients attained pCR and 1 more patient attained ypTmic.
  • For more information about the Phase 1 study, visit ClinicalTrials.gov: NCT04081389 .

SIBIONICS Launches the Breakthrough SIBIO KS1 CKM for Ketone Level Monitoring

Retrieved on: 
Tuesday, September 5, 2023
CGM, CKM, CE, IPX8, Acidosis, Senior, Electronics, Health, Biomarker, Ketosis, Certification, Swimming, Glucose meter, Reading, KS1

SHENZHEN, China, Sept. 5, 2023 /PRNewswire/ -- SIBIONICS, a leader in bio-wearable consumer electronics, is pleased to announce the launch of SIBIO KS1 Continuous Ketone Monitoring (CKM) System, the company's newest biometric wearable device designed to measure ketone levels.

Key Points: 
  • SHENZHEN, China, Sept. 5, 2023 /PRNewswire/ -- SIBIONICS, a leader in bio-wearable consumer electronics, is pleased to announce the launch of SIBIO KS1 Continuous Ketone Monitoring (CKM) System, the company's newest biometric wearable device designed to measure ketone levels.
  • Boasting CE certification for wearable biosensors for monitoring healthcare, the KS1 is the world's first all-in-one sensor and transmitter that provides real-time monitoring for ketone diet practitioners.
  • "The purpose for developing the SIBIO KS1 CKM was to expand the previous biometric sensing technology SIBIONICS has already mastered to provide higher quality and more precise monitoring capabilities.
  • SIBIONICS has announced the free trial availability of the SIBIO KS1 CKM.